---
title: Identification the Cause of Cerebral Infarction in Patients With Cancer
nct_id: NCT02212496
overall_status: COMPLETED
sponsor: Samsung Medical Center
study_type: OBSERVATIONAL
primary_condition: Cryptogenic Embolic Stroke
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02212496.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02212496"
ct_last_update_post_date: 2019-07-05
last_seen_at: "2026-05-12T06:59:39.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Identification the Cause of Cerebral Infarction in Patients With Cancer

**NCT ID:** [NCT02212496](https://clinicaltrials.gov/study/NCT02212496)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 118
- **Lead Sponsor:** Samsung Medical Center
- **Conditions:** Cryptogenic Embolic Stroke, Active Cancer
- **Start Date:** 2014-08
- **Completion Date:** 2018-03
- **CT.gov Last Update:** 2019-07-05

## Brief Summary

Although there has been increasing interest in the association between cancer and cerebrovascular disease, the underlying pathophysiology of stroke in cancer patients is still not fully understood. The aim of this study is to investigate the stroke mechanisms in patients with cancer-associated stroke.

## Detailed Description

Patients with cryptogenic embolic stroke will be prospectively enrolled and categorized into two groups according to the presence of active cancer: cryptogenic embolic stroke with active cancer (cancer-associated stroke) vs. without active cancer (cryptogenic embolic stroke). All patients will undergo brain MRI/MRA, 12-lead electrocardiography, transthoracic and transesophageal echocardiography with injection of agitated saline, and 24-hour Holter and/or telemonitoring. Duplex ultrasonography to detect venous thrombosis of the lower extremity will also be performed in patients with a positive right-to-left shunt on echocardiography.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Subjects with acute ischemic stroke who presented within 7 days from symptom onset
* Subjects who had embolic infarction outside the perforator territory revealed by diffusion-weighted imaging
* Subjects with undetermined cause of stroke despite of initial evaluation including electrocardiogram and brain imaging upon admission
* Subjects who performed brain magnetic resonance image (MRI) and MR angiography (MRA), cardiac work-ups (12-lead electrocardiography, transthoracic and/or transesophageal echocardiography with injection of agitated saline (or agitated saline transcranial Doppler monitoring), and 24-hour Holter and/or telemonitoring)
* Subjects with informed consent

Exclusion Criteria:

* Subjects with single subcortical infarction
* Subjects with primary brain tumor
* Inability to perform comprehensive studies
* Refusal or withdrawal of the consent
```

## Arms

- **Cancer-associated stroke** — Cryptogenic embolic stroke with active cancer
- **Cryptogenic embolic stroke** — Cryptogenic embolic stroke without active cancer

## Primary Outcomes

- **Prevalence of deep vein thrombosis and microembolic signal in cancer related stroke patients** _(time frame: Within one week after enrollment)_ — Venous thromboembolism was investigated via Doppler sonography and/or computed tomography pulmonary angiography combined with venous phase CT angiography of the lower extremities. Microembolic signal was detected via transcranial Doppler sonography on symptomatic cerebral circulation

## Secondary Outcomes

- **Impact of intravascular thrombosis on infarct volume** _(time frame: Within one week after enrollment)_
- **Impact of intravascular thrombosis on survival** _(time frame: Till the event of death occurs in enrolled patients)_

## Locations (1)

- Samsung Medical Center, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.samsung medical center|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02212496.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02212496*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*